

## Reference list

### Included studies

Adachi JD, Bensen WG, Bianchi F et al. (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up. *Journal of Rheumatology* 23: 995–1000.

Adachi JD, Bensen WG, Brown J et al. (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *New England Journal of Medicine* 337: 382–7.

Adachi JD, Saag KG, Delmas PD et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis and Rheumatism* 44: 202–11.

Adami S (2006) Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. *Bone* 38: 23–7.

Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *Journal of the American Medical Association* 291: 1701–12.

Avenell A, Grant AM, McGee M et al. (2004) The effects of an open design on trial participant recruitment, compliance and retention – a randomized controlled trial comparison with a blinded, placebo-controlled design. *Clinical Trials* 1:490–8.

Bagger YZ, Tanko LB, Alexandersen P et al. (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. *Bone* 34: 728–35.

Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. *Lancet* 348: 1535–41.

Black DM, Thompson DE, Bauer DC et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. *Journal of Clinical Endocrinology and Metabolism* 85: 4118–24 (erratum appears in *Journal of Clinical Endocrinology and Metabolism* 86: 938).

Black DM, Greenspan SL, Ensrud KE et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *New England Journal of Medicine* 349: 1207–15.

Black DM, Bilezikian JP, Ensrud KE et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *New England Journal of Medicine* 353: 555–65.

Black DM, Schwartz AV, Ensrud KE et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *Journal of the American Medical Association* 296: 2927–38.

Black DM, Delmas PD, Eastell R et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *New England Journal of Medicine* 356: 1809–22.

Bone HG, Downs RW Jr, Tucci JR et al. (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. *Journal of Clinical Endocrinology and Metabolism* 82: 265–74.

Bone HG, Greenspan SL, McKeever C et al. (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density.

Alendronate/Estrogen Study Group. *Journal of Clinical Endocrinology and Metabolism* 85: 720–6.

Bone HG, Hosking D, Devogelaer JP et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. *New England Journal of Medicine* 350: 1189–99.

Bonnick S, Saag KG, Kiel DP et al. (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. *Journal of Clinical Endocrinology and Metabolism* 91:2631–7.

Boonen S, Marin F, Mellstrom D et al. (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. *Journal of the American Geriatrics Society* 54: 782–9.

Campbell IA, Douglas JG, Francis RM et al. (2004) Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. *Thorax* 59:761–8.

Carfora E, Sergio F, Bellini P et al. (1998) Effect of treatment of postmenopausal osteoporosis with continuous daily oral alendronate and the incidence of fractures. *Gazzetta Medica Italiana – Archivio Per Le Scienze Mediche* 157: 105–9.

Chapuy MC, Arlot ME, Duboeuf F et al. (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. *New England Journal of Medicine* 327:1637–42.

Chapuy MC, Pamphile R, Paris E et al. (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. *Osteoporosis International* 13:257–64.

Chesnut-III CH, Silverman S, Andriano K et al. (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. *American Journal of Medicine* 109: 267–76.

Chesnut-III CH, Skag A, Christiansen C et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *Journal of Bone and Mineral Research* 19:1241–9.

Chesnut CH, Ettinger MP, Miller PD et al. (2005) Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. *Current Medical Research and Opinion* 21:391–401.

Chevalley T, Rizzoli R, Nydegger V et al. (1994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. *Osteoporosis International* 4: 245–52.

Cohen S, Levy RM, Keller M et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis and Rheumatism* 42: 2309–18.

Cortet B, Hachulla E, Barton I et al. (1999) Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. *Revue Du Rhumatisme* 66:214–9.

Cosman F, Nieves J, Woelfert L et al. (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. *Journal of Bone and Mineral Research* 16: 925–31.

Cosman F, Nieves J, Zion M et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. *New England Journal of Medicine* 353: 566–75.

Crans GG, Silverman SL, Genant HK et al. (2004) Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. *Arthritis and Rheumatism* 50: 4028–34.

Cummings SR, Black DM, Thompson DE et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. *Journal of the American Medical Association* 280: 2077–82.

Dawson HB, Harris SS, Krall EA et al. (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *New England Journal of Medicine* 337:670–6.

Delmas PD, Recker RR, Chesnut CH et al. (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. *Osteoporosis International* 15:792–8.

Delmas PD, Adami S, Strugala C et al. (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. *Arthritis and Rheumatism* 54:1838–46.

Dempster DW, Cosman F, Kurland ES et al. (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. *Journal of Bone and Mineral Research* 16: 1846–53.

Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. *International Journal of Clinical Practice* 55: 505–9.

Ebeling PR, Wark JD, Yeung S et al. (2001) Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. *Journal of Clinical Endocrinology and Metabolism* 86: 4098–103.

Eisman JA, Civitelli R, Adami S et al. (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. *Journal of Rheumatology* 35: 488–97.

Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. *Journal of the American Medical Association* 282: 637–45.

Evio S, Tiitinen A, Laitinen K et al. (2004) Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. *Journal of Clinical Endocrinology and Metabolism* 89: 626–31.

Falch JA, Odegaard OR, Finnanger AM et al. (1987) Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. *Acta Medica Scandinavica* 221: 199–204.

Felsenberg D, Miller P, Armbrecht G et al. (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. *Bone* 37: 651–4.

Fogelman I, Ribot C, Smith R et al. (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. *Journal of Clinical Endocrinology and Metabolism* 85: 1895–900.

Frisoli A, Chaves PH, Pinheiro MM et al. (2005) The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in

elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 60: 648–53.

Gallagher JC, Riggs BL, Recker RR et al. (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. *Proceedings of the Society for Experimental Biology and Medicine* 191: 287–92.

Gallagher JC, Fowler SE, Detter JR et al. (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. *Journal of Clinical Endocrinology and Metabolism* 86: 3618–28.

Gallagher JC, Genant HK, Crans GG et al. (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. *Journal of Clinical Endocrinology and Metabolism* 90: 1583–7.

Gallagher JC, Rosen CJ, Chen P et al. (2006) Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. *Bone* 39: 1268–75.

Genant HK, Siris E, Crans GG et al. (2005) Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. *Bone* 37: 170–4.

Geusens P, Dequeker J (1986) Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. *Bone and Mineral* 1: 347–57.

Geusens P, Dequeker J, Vanhoof J et al. (1998) Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study *Annals of the Rheumatic Diseases* 57: 724–7.

Grant AM, Avenell A, Campbell MK et al. (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 365: 1621–8.

Greenspan SL, Resnick NM, Parker RA (2003) Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. *Journal of the American Medical Association* 289: 2525–33.

Greenspan SL, Bone HG, Ettinger MP (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. *Annals of Internal Medicine* 146: 326–39.

Greenspan SL, Schneider DL, McClung MR et al. (2002) Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 136: 742–6.

Hansson T, Roos B (1987) The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. *Calcified Tissue International* 40: 315–7.

Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. *Journal of the American Medical Association* 282: 1344–52.

Harwood RH, Sahota O, Gaynor K et al. (2004) A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study. *Age and Ageing* 33: 45–51.

Herd RJ, Balena R, Blake GM et al. (1997) The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. *American Journal of Medicine* 103: 92–9.

Herrington DM, Reboussin DM, Brosnihan KB et al. (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. *New England Journal of Medicine* 343: 522–9.

Hochberg MC, Thompson DE, Black DM et al. (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. *Journal of Bone and Mineral Research* 20: 971–6.

Hooper MJ, Ebeling PR, Roberts AP et al. (2005) Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. *Climacteric* 8: 251–62.

Hosking D, Chilvers CE, Christiansen C et al. (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. *New England Journal of Medicine* 338: 485–92.

Jackson RD, LaCroix AZ, Gass M et al. (2006) Calcium plus vitamin D supplementation and the risk of fractures. *New England Journal of Medicine* 354: 669–83.

Jenkins EA, Walker-Bone KE, Wood A et al. (1999) The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. *Scandinavian Journal of Rheumatology* 28: 152–6.

Jiang Y, Zhao JJ, Mitlak BH et al. (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. *Journal of Bone and Mineral Research* 18: 1932–41.

Kaufman JM, Orwoll E, Goemaere S et al. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. *Osteoporosis International* 16: 510–6.

Komulainen MH, Kröger H, Tuppurainen MT et al. (1998) HRT and Vitamin D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. *Maturitas* 31: 45–54.

Kurland ES, Cosman F, McMahon DJ et al. (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. *Journal of Clinical Endocrinology and Metabolism* 85: 3069–76.

Lane NE, Sanchez S, Modin GW et al. (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. *Journal of Clinical Investigation* 102: 1627–33.

Lane NE, Sanchez S, Genant HK et al. (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. *Osteoporosis International* 11: 434-42.

Lane NE, Sanchez S, Modin GW et al. (2000) Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. *Journal of Bone and Mineral Research* 15: 944–51.

Larsen ER, Mosekilde L, Foldspang A (2004) Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. *Journal of Bone and Mineral Research* 19: 370–8.

Liberman UA, Weiss SR, Bröll J et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.

The Alendronate Phase III Osteoporosis Treatment Study Group. *New England Journal of Medicine* 333: 1437–43.

Lindsay R, Nieves J, Formica C et al. (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. *Lancet* 350: 550–5.

Lindsay R, Cosman F, Lobo RA et al. (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism* 84: 3076–81.

Lindsay R, Scheele WH, Neer R et al. (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. *Archives of Internal Medicine* 164: 2024–30.

Lips P, Graafmans WC, Ooms ME et al. (1996) Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. *Annals of Internal Medicine* 124: 400–6.

Luckey M, Kagan R, Greenspan S et al. (2004) Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. *Menopause* 11: 405–15.

Luengo M, Pons F, Martinez-de-Osaba MJ et al. (1994) Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. *Thorax* 49: 1099–102.

Lufkin EG, Wahner HW, Fallon WM et al. (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. *Annals of Internal Medicine* 117: 1–9.

Lufkin EG, Whitaker MD, Nickelsen T et al. (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. *Journal of Bone and Mineral Research* 13: 1747–54.

Lyles KW, Colon-Emeric CS, Magaziner JS et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. *New England Journal of Medicine* 357: 1799–809.

Lyons RA, Johansen A, Brophy S et al. (2007) Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. *Osteoporosis International* 18: 811–8.

Marcus R, Wang O, Satterwhite J et al. (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. *Journal of Bone and Mineral Research* 18: 18–23.

McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. *New England Journal of Medicine* 344: 333–40.

McClung MR, San Martin J, Miller PD et al. (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. *Archives of Internal Medicine* 165: 1762–8 (erratum appears in *Archives of Internal Medicine*. 165: 2120).

Mebane SI, Bush TL, Wells HB et al. (1996) Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. *Journal of the American Medical Association* 276: 1389–96.

Mellstrom DD, Sorensen OH, Goemaere S et al. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. *Calcified Tissue International* 75: 462–8.

Meunier PJ, Confavreux E, Tupinon I et al. (1997) Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind,

placebo-controlled study and 1-year follow-up). *Journal of Clinical Endocrinology and Metabolism* 82:2784–91.

Meunier PJ, Slosman DO, Delmas PD et al. (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis – a 2-year randomized placebo controlled trial. *Journal of Clinical Endocrinology and Metabolism* 87: 2060–6.

Meunier PJ, Roux C, Seeman E et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *New England Journal of Medicine* 350: 459–68.

Meyer HE, Smedshaug GB, Kvaavik E et al. (2002) Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. *Journal of Bone and Mineral Research* 17: 709–15.

Michalska D, Stepan JJ, Basson BR et al. (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. *Journal of Clinical Endocrinology and Metabolism* 91: 870–7.

Miller PD, Schnitzer T, Emkey R et al. (2004) Weekly oral alendronic acid in male osteoporosis. *Clinical Drug Investigation* 24: 333–41.

Miller PD, McClung MR, Macovei L et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. *Journal of Bone and Mineral Research* 20: 1315–22.

Miller PD, Schwartz EN, Chen P et al. (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. *Osteoporosis International* 18: 59–68.

Miller PD, Epstein S, Sedarati F et al. (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. *Current Medical Research and Opinion* 24: 207–13.

Montessori ML, Scheele WH, Netelenbos JC et al. (1997) The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. *Osteoporosis International* 7: 52–8.

Mortensen L, Charles P, Bekker PJ et al. (1998) Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. *Journal of Clinical Endocrinology and Metabolism* 83: 396–402.

Mosekilde L, Beck NH, Sorensen OH et al. (2000) Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women – results of the Danish Osteoporosis Prevention Study. *Maturitas* 36: 181–93.

Musco E, Puglisi N, Mamazza C et al. (2004) Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study. *European Review for Medical and Pharmacological Sciences* 8: 97–102.

Neer RM, Arnaud CD, Zanchetta JR et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *New England Journal of Medicine* 344: 1434–41.

Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. *New England Journal of Medicine* 343: 604–10.

Orwoll ES, Scheele WH, Paul S et al. (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. *Journal of Bone and Mineral Research* 18: 9–17.

Overgaard K, Hansen MA, Jensen SB et al. (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. *BMJ* 305: 556–61.

Pacifici R, McMurtry C, Vered I et al. (1988) Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. *Journal of Clinical Endocrinology and Metabolism* 66: 747–53.

Palomba S, Orio F Jr, Russo T et al. (2005) Bsm1 vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. *Osteoporosis International* 16: 943–52.

Passeri M, Pedrazzoni M, Pioli G et al. (1993) Effects of nandrolone decanoate on bone mass in established osteoporosis. *Maturitas* 17: 211–9.

Peacock M, Liu G, Carey M et al. (2000) Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. *Journal of Clinical Endocrinology and Metabolism* 85: 3011–9.

Pfeifer M, Begerow B, Minne HW et al. (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *Journal of Bone and Mineral Research* 15: 1113-8.

Pols HA, Felsenberg D, Hanley DA et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. *Osteoporosis International* 9: 461–8.

Porthouse J, Cockayne S, King C et al. (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. *BMJ* 330: 1003.

Pouilles JM, Tremollieres F, Roux C et al. (1997) Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. *Osteoporosis International* 7: 213-8.

Prince R, Sipos A, Hossain A et al. (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. *Journal of Bone and Mineral Research* 20: 1507–13.

Prince RL, Devine A, Dhaliwal SS et al. (2006) Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year,

double-blind, placebo-controlled trial in elderly women. *Archives of Internal Medicine* 166: 869–75.

Ravn P, Bidstrup M, Wasnich RD et al. (1999) Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. *Annals of Internal Medicine* 131: 935–42.

Recker RR, Hinders S, Davies KM et al. (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. *Journal of Bone and Mineral Research*. 11: 1961–6.

Recker RR, Kendler D, Recknor CP et al. (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. *Bone* 40: 843–51.

Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. *Osteoporosis International* 11: 83–91.

Reginster JY, Felsenberg D, Pavo I et al. (2003) Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. *Osteoporosis International* 14: 741–9.

Reginster JY, Seeman E, De Vernejoul MC et al. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. *Journal of Clinical Endocrinology and Metabolism* 90: 2816–22.

Reginster JY, Adami S, Lakatos P et al. (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. *Annals of Rheumatic Diseases* 65: 654-61.

Reginster JY, Malaise O, Neuprez A et al. (2007) Strontium ranelate in the prevention of osteoporotic fractures. *International Journal of Clinical Practice* 61: 324–8.

Reid DM, Hughes RA, Laan RF et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *European Corticosteroid-Induced Osteoporosis Treatment Study. Journal of Bone and Mineral Research* 15: 1006–13.

Reid DM, Hosking D, Kendler D et al. (2006b) Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS-international. *Clinical Drug Investigation* 26: 63–74.

Reid DM, Hosking D, Kendler D et al. (2008) A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. *International Journal of Clinical Practice* 62: 575–84.

Reid IR, Ames RW, Evans MC et al. (1993) Effect of calcium supplementation on bone loss in postmenopausal women. *New England Journal of Medicine* 328: 460–4 (erratum appears in *New England Journal of Medicine* 329: 1281).

Reid IR, Ames RW, Evans MC et al. (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. *American Journal of Medicine* 98: 331–5.

Reid IR, Mason B, Horne A et al. (2006) Randomized controlled trial of calcium in healthy older women. *American Journal of Medicine* 119: 777–85.

Riggs BL, Fallon WM, Muhs J et al. (1998) Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. *Journal of Bone and Mineral Research* 13: 168–74.

Rosen CJ, Hochberg MC, Bonnick SL et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. *Journal of Bone and Mineral Research* 20: 141–51.

Roux C, Oriente P, Laan R et al. (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. *Ciblos Study Group. Journal of Clinical Endocrinology and Metabolism* 83: 1128–33.

Saag KG, Emkey R, Schnitzer TJ et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *Glucocorticoid-Induced Osteoporosis Intervention Study Group. New England Journal of Medicine* 339: 292–9.

Sambrook PN, Geusens P, Ribot C et al. (2004) Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. *Journal of Internal Medicine* 255: 503–11.

Sarioglu M, Tuzun C, Unlu Z et al. (2006) Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. *Rheumatology International* 26: 195–200.

Sebba AI, Bonnick SL, Kagan R et al. (2004) Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. *Current Medical Research and Opinion* 20: 2031–41.

Seeman E (1999) The antifracture efficacy of alendronate. *International Journal of Clinical Practice (Suppl)* 101: 40–5.

Smith H, Anderson F, Raphael H et al. (2007) Effect of annual intramuscular vitamin D on fracture risk in elderly men and women –a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology* 46:1852–7.

Sorensen OH, Crawford GM, Mulder H et al. (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. *Bone* 32: 120–6.

Ste-Marie LG, Sod E, Johnson T et al. (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. *Calcified Tissue International* 75: 469–76.

Stock JL, Avioli LV, Baylink DJ et al. (1997) Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three year interim results of the PROOF study. *Journal of Bone and Mineral Research* 12 (Suppl. 1): S149.

Tilyard MW, Spears GF, Thomson J et al. (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. *New England Journal of Medicine* 326: 357–62.

Toth E, Csupor E, Meszaros S et al. (2005) The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures – an open label study. *Bone* 36: 47–51.

Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 326: 469.

Watts NB, Harris ST, Genant HK et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. *New England Journal of Medicine* 323: 73–9.

Weiss SR, Ellman H, Dolker M (1999) A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. *Transdermal Estradiol Investigator Group. Obstetrics and Gynecology* 94: 330–6.

Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. *American Journal of Medicine* 104: 219–26.

### **Excluded studies**

Aapro M (2006) Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. *Breast* 15 (Suppl. 1): S30–S40.

Abellan PM, Bayina-Garcia FJ, Calabozo M et al. (1995) [Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis]. [Spanish] *Anales De Medicina Interna* 12: 12–6.

Adachi J, Cranney A, Goldsmith CH et al. (1994) Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. *Journal of Rheumatology* 21: 1922–6.

Adami S, Passeri M, Ortolani S et al. (1995) Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. *Bone* 17: 383–90.

Adami S, Felsenberg D, Christiansen C et al. (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. *Bone* 34: 881–9.

Ahlborg HG, Johnell O, Karlsson MK (2004) Long term effects of oestrogen therapy on bone loss in postmenopausal women: a 23 year prospective study. *British Journal of Obstetrics and Gynaecology* 111: 335–9.

Al Azzawi F, Lees B, Thompson J et al. (2005) Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. *Menopause* 12: 331–9.

Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. *Journal of Clinical Endocrinology and Metabolism* 84: 3013–20.

Aloia JF, Vaswani A, Yeh JK et al. (1988) Calcitriol in the treatment of postmenopausal osteoporosis. *American Journal of Medicine* 84: 401–8.

Aris RM, Lester GE, Caminiti M et al. (2004) Efficacy of alendronate in adults with cystic fibrosis with low bone density. *American Journal of Respiratory and Critical Care Medicine* 169: 77–82.

Arlot M, Meunier PJ, Boivin G et al. (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. *Journal of Bone and Mineral Research* 20: 1244–53.

Arthur RS, Piraino B, Candib D et al. (1990) Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. *Mineral and Electrolyte Metabolism* 16: 385–90.

Atmaca A, Gedik O (2006) Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis. *Advances in Therapy* 23: 842–53.

Baeksgaard L, Andersen KP, Hyldstrup L (1998) Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. *Osteoporosis International* 8: 255–60.

Barone A, Giusti A, Pioli G et al. (2007) Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. *Journal of the American Geriatrics Society* 55: 752–7.

Bauman WA, Spungen AM, Morrison N et al. (2005) Effect of a vitamin D analog on leg bone mineral density in patients with chronic spinal cord injury. *Journal of Rehabilitation Research and Development* 42: 625–33.

Bergstrom I, Freyschuss B, Landgren B-M (2005) Physical training and hormone replacement therapy reduce the decrease in bone mineral density in perimenopausal women: A pilot study. *Osteoporosis International* 16: 823–8.

Bhattoa HP, Bettembuk P, Balogh A et al. (2004) The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. *Osteoporosis International* 15: 396–404.

Birkenhager JC, Erdtsieck RJ, Zeelenberg J et al. (1992) Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis? *Bone and Mineral* 18: 251–65.

Black DM, Bilezikian JP, Ensrud KE et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *New England Journal of Medicine* 353: 555–65.

Body JJ, Gaich GA, Scheele WH et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. *Journal of Clinical Endocrinology and Metabolism* 87: 4528–35.

Body JJ, Diel IJ, Lichinitzer M et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. *British Journal of Cancer* 90: 1133–7.

Bone HG, Greenspan SL, McKeever C et al. (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. *Journal of Clinical Endocrinology and Metabolism* 85: 720–6.

Boone RH, Cheung AM, Girlan LM et al. (2006) Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. *Digestive Diseases and Sciences* 51: 1103–12.

Braith RW, Conner JA, Fulton MN et al. (2007) Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. *Journal of Heart and Lung Transplantation* 26: 132–7.

Brufsky A, Harker WG, Beck JT et al. (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. *Journal of Clinical Oncology* 25: 829–36.

Buckley LM, Leib ES, Cartularo KS et al. (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 125: 961–8.

Caniggia A, Delling G, Nuti R et al. (1984) Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. *Acta Vitaminologica et Enzymologica*. 6: 117–28.

Cauley JA, Zmuda JM, Ensrud KE et al. (2001) Timing of estrogen replacement therapy for optimal osteoporosis prevention. *Journal of Clinical Endocrinology and Metabolism* 86: 5700–5.

Cauley JA, Robbins J, Chen Z et al. (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *Journal of the American Medical Association* 290: 1729–38.

Chesnut CH III, McClung MR, Ensrud KE et al. (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. *American Journal of Medicine* 99: 144–52.

Clemmesen B, Ravn P, Zegels B et al. (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. *Osteoporosis International* 7: 488–95.

Crawford BA, Kam C, Pavlovic J et al. (2006) Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 144: 239–48 (summary for patients appears in *Annals of Internal Medicine* 144: 137).

Cristallini S, Pedetti M, Donatelli C et al. (1993) [The effect of different "coherent"-type therapeutic plans on bone mineral density and on the incidence of vertebral fractures in advanced osteoporosis]. *Recenti Progressi in Medicina* 84: 336–45.

Davis SR, Dinatale I, Rivera-Woll L et al. (2005) Postmenopausal hormone therapy: from monkey glands to transdermal patches. *Journal of Endocrinology* 185: 207–22.

Delmas PD, Marianowski L, Perez AC et al. (2004) Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route. *Maturitas* 48: 85–96.

Deng WM, Cui WL, Shen YG et al. (2004) Comparative analysis of the integrate therapeutic effectiveness of Bushen Zhuanggu medicament and calcitonin in treating menopausal osteoporosis. *Chinese Journal of Clinical Rehabilitation* 8: 2973.

Di Munno O, Beghe F, Favini P et al. (1989) Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. *Clinical Rheumatology* 8: 202–7.

Doren M, Nilsson JA, Johnell O (2003) Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis (DARE structured abstract). *Human Reproduction* 18: 1737–46.

Dukas L, Bischoff HA, Lindpaintner LS et al. (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. *Journal of the American Geriatrics Society* 52: 230–6.

Dukas L, Schacht E, Mazor Z et al. (2005) Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. *Osteoporosis International* 16:198–203.

Durchschlag E, Paschalis EP, Zoehrer R et al. (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. *Journal of Bone and Mineral Research* 21: 1581–90.

Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. *International Journal of Clinical Practice* 55: 505–9.

Dykman TR, Haralson KM, Gluck OS et al. (1984) Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. *Arthritis and Rheumatism* 27:1336–43.

El Agroudy AE, El Hussein AA, El Sayed M et al. (2005) A prospective randomized study for prevention of postrenal transplantation bone loss. *Kidney International* 67: 2039–45.

El Hussein AA, El Agroudy AE, El Sayed MF et al. (2004) Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. *Pediatric Transplantation* 8: 357–61.

Ellerington MC, Hillard TC, Whitcroft S I et al. (1996) Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. *Calcified Tissue International* 59: 6–11.

Erdtsieck RJ, Pols HA, van Kuijk C et al. (1994) Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. *Journal of Bone and Mineral Research* 9: 277–83.

Finkelstein JS, Klibanski A, Arnold AL et al. (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. *Journal of the American Medical Association* 280: 1067–73.

Finkelstein JS, Hayes A, Hunzelman JL et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. *New England Journal of Medicine* 349: 1216–26.

Frost RJ, Sonne C, Wehr U et al. (2007) Effects of calcium supplementation on bone loss and fractures in congestive heart failure. *European Journal of Endocrinology* 156: 309–14.

Fujita T, Inoue T, Morii H et al. 1999) Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. *Osteoporosis International* 9: 296–306.

Fujita T, Fujii Y, Okada SF et al. (2001) Analgesic effect of etidronate on degenerative joint disease. *Journal of Bone and Mineral Metabolism* 19: 251–6.

Fujita T, Orimo H, Inoue T et al. (2007) Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol. *Journal of Bone and Mineral Metabolism* 25: 130–7.

Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. *Annals of Internal Medicine* 113: 649–55.

Gilfillan CP, Strauss BJ, Rodda CP et al. (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. *Calcified Tissue International* 79: 138–44.

Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. *Journal of Clinical Oncology* 25: 820–8.

Golden NH, Iglesias EA, Jacobson MS et al. (2005) Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. *Journal of Clinical Endocrinology and Metabolism* 90: 3179–85.

Gonnelli S, Martini G, Caffarelli C et al. (2006) Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. *Osteoporosis International* 17: 1524–31.

Gorai I, Chaki O, Taguchi Y et al. (1999) Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. *Calcified Tissue International* 65: 16–22.

Graafmans WC, Ooms ME, Hofstee HM et al. (1996) Falls in the elderly: a prospective study of risk factors and risk profiles. *American Journal of Epidemiology* 143: 1129–36.

Greenspan SL, Resnick NM, Parker RA (2003) Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly

women: a randomized controlled trial. *Journal of the American Medical Association* 289: 2525–33.

Greenspan SL, Beck TJ, Resnick NM et al. (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. *Journal of Bone and Mineral Research* 20: 1525–32.

Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. *Journal of Clinical Endocrinology and Metabolism* 90: 2762–7.

Greenspan SL, Nelson JB, Trump DL et al. (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. *Annals of Internal Medicine* 146: 416–24.

Greenspan SL, Bhattacharya RK, Sereika SM et al. (2007) Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism* 92: 131–6.

Guaraldi G, Orlando G, Madeddu G et al. (2004) Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. *HIV Clinical Trials* 5: 269–77.

Hasegawa J, Nagashima M, Yamamoto M et al. (2003) Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. *Journal of Rheumatology* 30:474–9.

Hay JE, Malinchoc M, Dickson ER (2001) A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. *Journal of Hepatology* 34: 292–8.

Henderson K, Eisman J, Keogh A et al. (2001) Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. *Journal of Bone and Mineral Research* 16: 565–71.

Henderson S, Hoffman N, Prince R (2006) A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. *American Journal of Gastroenterology* 101: 119–23.

Higashiyama S, Shiomi S, Kawamura E et al. (2006) Effect of alendronate on bone loss in patients with cirrhosis of the liver. *Japanese Pharmacology and Therapeutics* 34: 1209–14.

Hizmetli S, Elden H, Kaptanoglu E et al. (1998) The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis. *International Journal of Clinical Practice* 52: 453–5.

Ho AY, Kung AW (2005) Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. *Annals of Pharmacotherapy* 39: 1428–33.

Hodsman AB, Fraher LJ, Watson PH et al. (1997) A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. *Journal of Clinical Endocrinology and Metabolism* 82: 620–8.

Hosking D, Chilvers CED, Christiansen C et al. (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. *New England Journal of Medicine* 338: 485–92.

Hwang JS, Tu ST, Yang TS et al. (2006) Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. *Osteoporosis International* 17: 373–8.

Ikeda T, Manabe H, Iwata K (2004) Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus. *Diabetes and Metabolism* 30: 355–8.

Inkovaara J, Gothoni G, Halttula R et al. (1983) Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. *Age and Ageing* 12: 124–30.

Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. *American Journal of Medicine* 117: 549–55.

Iwamoto J, Takeda T, Ichimura S (2001) Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. *Journal of Orthopaedic Science* 6: 487–92.

Jinnouchi Y (2000) Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease. *Kurume Medical Journal* 47: 219–24.

Kanaji A, Higashi M, Namisato M et al. (2006) Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. *Leprosy Review* 77: 147–53.

Karachalios T, Lyritis GP, Kaloudis J et al. (2004) The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial. *Journal of Bone and Joint Surgery Series B* 86: 350.

Kasayama S, Fujita M, Goya K et al. (2005) Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. *Metabolism: Clinical and Experimental* 54: 85–90.

Kaskani E, Lyritis GP, Kosmidis C et al. (2005) Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study. *Clinical Rheumatology* 24: 232–8.

Keegan TH, Schwartz AV, Bauer DC et al. (2004) Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. *Diabetes Care* 27: 1547–53.

Kishimoto H, Fukunaga M, Kushida K et al. (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. *Journal of Bone and Mineral Metabolism* 24: 405–13.

Kung AW, Chan TM, Lau CS et al. (1999) Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. *Rheumatology* 38: 1239–44.

Kushida K, Fukunaga M, Kishimoto H et al. (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. *Journal of Bone and Mineral Metabolism* 22:469–78.

Lakatos P, Nagy Z, Kiss L et al. (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. *Zeitschrift fur Rheumatologie* 59 (Suppl. 1): 48–52.

Lambrinoudaki I, Chan DT, Lau CS et al. (2000) Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. *Journal of Rheumatology* 27: 1759–65.

Law M, Withers H, Morris J, Anderson F (2006) Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. *Age and Ageing* 35: 482–6.

Leidig BG, Eberwein S, Bruckner T et al. (1997) Long term follow-up of lumbar and femoral bone mineral density and vertebral fractures in patients with manifest postmenopausal osteoporosis after fluoride therapy alone or combined with estrogens or anabolica. *Experimental and Clinical Endocrinology and Diabetes* 105: A58.

Leung JY, Ho AY, Ip TP et al. (2005) The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. *Bone* 36: 358–64.

Lindor KD, Jorgensen RA, Tiegs RD et al. (2000) Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. *Journal of Hepatology* 33:878–82.

Lindsay R, Cosman F, Lobo RA et al. (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism* 84: 3076–81.

Lovell DJ, Glass D, Ranz J et al. (2006) A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. *Arthritis and Rheumatism* 54: 2235–42.

Lydeking-Olsen E, Beck-Jensen JE, Setchell KD et al. (2004) Soymilk or progesterone for prevention of bone loss – a 2 year randomized, placebo-controlled trial. *European Journal of Nutrition* 43: 246–57.

Lyritys GP, Tsakalacos N, Paspati I et al. (1997) The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. *Clinical Rheumatology* 16: 354–60.

Matsumoto T, Miki T, Hagino H et al. (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism* 90: 5031–6.

Matsumoto T, Shiraki M, Hagino H (2006) Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: A pilot study. *Osteoporosis International* 17: 1532–8.

McClung M, Clemmesen B, Daifotis A et al. (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis – A double-blind, randomized, controlled trial. *Annals of Internal Medicine* 128: 253–61.

McClung MR, Wasnich RD, Hosking DJ et al. (2004) Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. *Journal of Clinical Endocrinology and Metabolism* 89: 4879–85.

McClung MR, Siris E, Cummings S et al. (2006) Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. *Menopause* 13: 377–86.

McClung MR, Wasnich RD, Recker R et al. (2004) Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. *Journal of Bone and Mineral Research* 19: 11–8.

McDonald CF, Zebaze RMD, Seeman E (2006) Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: A double-blind placebo-controlled trial. *Osteoporosis International* 17:1546–51.

Menczel J, Foldes J, Steinberg R et al. (1994) Alfacalcidol (alpha D3) and calcium in osteoporosis. *Clinical Orthopaedics and Related Research* 300: 241–7.

Michaelson MD, Kaufman DS, Lee H et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. *Journal of Clinical Oncology* 25: 1038–42.

Mikati MA, Dib L, Yamout B et al. (2006) Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. *Neurology* 67: 2005–14.

Mizunuma H, Shiraki M, Shintani M et al. (2006) Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss. *Journal of Bone and Mineral Metabolism* 24: 11–5.

Mondy K, Powderly WG, Claxton SA et al. (2005) Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. *Journal of Acquired Immune Deficiency Syndromes* 38: 426–31.

Moran de Brito CM, Battistella LR, Saito ET et al. (2005) Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study. *Spinal Cord* 43: 341–8.

Nakahara T, Nagai N, Tanaka M et al. (2006) The effects of bone therapy on tibial bone loss in young women with anorexia nervosa. *International Journal of Eating Disorders* 39: 20–6.

Nakayamada S, Okada Y, Saito K et al. (2004) Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. *Journal of Rheumatology* 31: 163–6.

Negredo E, Martinez-Lopez E, Paredes R et al. (2005) Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. *AIDS* 19: 343–5.

Nuti R, Bianchi G, Brandi ML et al. (2006) Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. *Rheumatology International* 26: 445–53.

Orimo H, Shiraki M, Hayashi T et al. (1987) Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. *Bone and Mineral* 3: 47–52.

Orimo H, Shiraki M, Hayashi Y et al. (1994) Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. *Calcified Tissue International* 54: 370–6.

Ormarsdóttir S, Mallmin H, Naessén T et al. (2004) An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. *Journal of Internal Medicine* 256: 63–9.

Orwoll ES, McClung MR, Oviatt SK et al. (1989) Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis. *Journal of Bone and Mineral Research* 4: 81–8.

Otrock ZK, Azar ST, Shamseddeen WA et al. (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. *Annals of Hematology* 85: 605–9.

Ott SM, Chesnut CH III (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. *Annals of Internal Medicine* 110: 267–74.

Ott SM, Chesnut CH III (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. *Annals of Internal Medicine* 110: 267–74.

Pacifici R, McMurtry C, Vered I et al. (1988) Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. *Journal of Clinical Endocrinology and Metabolism* 66: 747–53.

Palomba S, Orio F Jr, Manguso F et al. (2005) Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. *Osteoporosis International* 16: 1141–9.

Peacock M, Liu G, Carey M et al. (2000) Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. *Journal of Clinical Endocrinology and Metabolism* 85: 3011–9.

Peichl P, Marteau R, Griesmacher A et al. (2005) Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. *Journal of Bone and Mineral Metabolism* 23: 243–52.

Pereira SP, O'Donohue J, Moniz C et al. (2004) Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. *Alimentary Pharmacology and Therapeutics* 19: 563–70.

Pitt P, Li F, Todd P et al. (1998) A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. *Thorax* 53: 351–6.

Pontiroli AE, Pajetta E, Calderara A et al. (1991) Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study. *Journal of Endocrinological Investigation* 14: 47–51.

Recker R, Stakkestad JA, Chesnut CH III et al. (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. *Bone* 34: 890–9.

Recker RR, Kendler D, Recknor CP et al. (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. *Bone* 40: 843–51.

Reeve J, Meunier PJ, Parsons JA et al. (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. *BMJ* 280: 1340–4.

Reeve J, Davies UM, Hesp R et al. (1990) Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. *BMJ* 301: 314–8.

Reginster JY, Kuntz D, Verdickt W et al. (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. *Osteoporosis International* 9: 75–81.

Rhee Y, Kang M, Min Y et al. (2006) Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. *Osteoporosis International* 17: 1801–7.

Rico H, Revilla M, Hernández ER et al. (1995) Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. *Calcified Tissue International* 56: 181–5.

Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. *European Journal of Clinical Pharmacology* 33: 35–9.

Ringe JD (1990) [Treatment of primary osteoporosis with calcium and salmon calcitonin]. *Deutsche Medizinische Wochenschrift* 115: 1176–82.

Ringe JD, Cöster A, Meng T et al. (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol /calcium versus vitamin D/calcium. *Calcified Tissue International* 65: 337–40.

Rodrigues P, Hering FO, Bruna P et al. (2007) Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. *International Journal of Urology* 14: 317–20.

Rossini M, Gatti D, Zamberlan N et al. (1994) Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. *Journal of Bone and Mineral Research* 9: 1833–7.

Ryan CW, Huo D, Bylow K et al. (2007) Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. *BJU International* 100: 70–5.

Sambrook P, Birmingham J, Kelly P et al. (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. *New England Journal of Medicine* 328: 1747–52.

Sambrook P, Henderson NK, Keogh A et al. (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. *Journal of Bone and Mineral Research* 15: 1818–24.

Sambrook PN, Rodriguez JP, Wasnich RD et al. (2004) Alendronate in the prevention of osteoporosis: 7-year follow-up. *Osteoporosis International* 15: 483–8.

Sato S, Ohosone Y, Suwa A et al. (2003) Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. *Journal of Rheumatology* 30: 2673–9.

Sato S, Takada T, Katsuki Y et al. (2007) Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. *Journal of Rheumatology* 35: 142–6.

Sato S, Takada T, Katsuki Y et al. (2008) Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. *Journal of Rheumatology* 35: 142–6.

Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. *Neurology* 49: 1273–8.

Sato Y, Maruoka H, Oizumi K (1997) Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation. *Stroke* 28: 736–9.

Sato Y, Kuno H, Kaji M et al. (1999) Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. *American Journal of Physical Medicine and Rehabilitation* 78: 457–63.

Sato Y, Manabe S, Kuno H et al. (1999) Amelioration of osteopenia and hypovitaminosis D by 1 alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. *Journal of Neurology, Neurosurgery, and Psychiatry* 66: 64–8.

Sato Y, Asoh T, Kaji M et al. (2000) Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. *Journal of Bone and Mineral Research* 15: 2487–94.

Sato Y, Iwamoto J, Kanoko T et al. (2005) Risedronate therapy for prevention of hip fracture after stroke in elderly women. *Neurology* 64: 811–6.

Sato Y, Honda Y, Iwamoto J (2006) Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial. *Bone* 39:1080–6.

Sato Y, Iwamoto J, Kanoko T et al. (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. *Movement Disorders* 21: 924–9.

Shane E, Addezzo V, Namerow PB et al. (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. *New England Journal of Medicine* 350: 767–76.

Shiomi S, Nishiguchi S, Kurooka H et al. (2002) Cyclical etidronate for treatment of osteopenia in patients with cirrhosis of the liver. *Hepatology Research* 22: 102–6.

Shiraki M, Kushida K, Yamazaki K et al. (1996) Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: A placebo-controlled, double-blind prospective study. *Endocrine Journal* 43: 211–20.

Shiraki M, Fukuchi M, Kiriyama T et al. (2004) Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis. *Journal of Bone and Mineral Metabolism* 22: 352–9.

Sicat BL (2004) Should postmenopausal hormone therapy be used to prevent osteoporosis? *Consultant Pharmacist* 19: 725–35.

Siffledeen JS, Fedorak RN, Siminoski K et al. (2005) Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. *Clinical Gastroenterology and Hepatology* 3: 122–32.

Skingle SJ, Moore DJ, Crisp AJ (1997) Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. *International Journal of Clinical Practice* 51: 364–7.

Smith BJ, Laslett LL, Pile KD et al. (2004) Randomized controlled trial of alendronate in airways disease and low bone mineral density. *Chronic Respiratory Disease* 1: 131–7.

Smith MR, Fallon MA, Lee H et al. (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. *Journal of Clinical Endocrinology and Metabolism* 89: 3841–6.

Sosa M, Lainez P, Arbelo A et al. (2000) The effect of 25-dihydroxyvitamin D on the bone mineral metabolism of elderly women with hip fracture. *Rheumatology* 39:1263–8.

Stakkestad JA, Benevolenskaya LI, Stepan JJ et al. (2003) Intravenous ibandronate injections given every three months: a new treatment option to

prevent bone loss in postmenopausal women. *Annals of the Rheumatic Diseases* 62: 969–75.

Ste-Marie LG, Schwartz SL, Hossain A et al. (2006) Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. *Journal of Bone and Mineral Research* 21: 283–91.

Stellon A, Davies A, Webb A et al. (1985) Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. *Postgraduate Medical Journal* 61: 791–6.

Stempfle HU, Werner C, Ehtler S et al. (1999) Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. *Transplantation* 68: 523–30.

Stempfle HU, Werner C, Siebert U et al. (2002) The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. *Transplantation* 73: 547–52.

Storm T, Thamsborg G, Steiniche T et al. (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. *New England Journal of Medicine* 322: 1265–71.

Strokosch GR, Friedman AJ, Wu S-C et al. (2006) Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. *Journal of Adolescent Health* 39: 819–27.

Szücs J, Horváth C, Kollin E et al. (1992) Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. *Calcified Tissue International* 50: 7–10.

Talalaj M, Gradowska L, Marcinowska SE et al. (1996) Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. *Transplantation Proceedings* 28: 3485–7.

Tascioglu F, Colak O, Armagan O et al. (2005) The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. *Rheumatology International* 26: 21–9.

Tekeoglu I, Adak B, Budancamanak M et al. (2005) Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis. *Rheumatology International* 26: 157–61.

Thiébaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. *American Journal of Medicine* 103: 298–307.

Torres A, Garcia S, Gomez A et al. (2004) Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. *Kidney International* 65: 705–12.

Uchida S, Taniguchi T, Shimizu T et al. (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. *Journal of Bone and Mineral Metabolism* 23: 382–8.

Ushiroyama T, Ikeda A, Sakai M et al. (2001) Effects of the combined use of calcitonin and 1  $\alpha$ -hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: A prospective study of long-term and continuous administration with low dose calcitonin. *Maturitas* 40: 229–38.

Valimaki MJ, Kinnunen K, Tahtela R et al. (1999) A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. *Osteoporosis International* 10: 128–36.

Van Cleemput J, Daenen W, Geusens P et al. (1996) Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. *Transplantation* 61: 1495–9.

Vieth R (2005) The role of vitamin D in the prevention of osteoporosis.. *Annals of Medicine* 37: 278–85.

Voskaridou E, Anagnostopoulos A, Konstantopoulos K et al. (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. *Haematologica* 91: 1193–202.

Warren MP, Miller KK, Olson WH et al. (2005) Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. *Contraception* 72: 206–11.

Wasnich RD, Bagger YZ, Hosking DJ et al. (2004) Changes in bone density and turnover after alendronate or estrogen withdrawal. *Menopause* 11: 622–30.

Wenstrup RJ, Bailey L, Grabowski GA et al. (2004) Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. *Blood* 104: 1253.

Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. *American Journal of Medicine* 104:219–26.

Wissing KM, Broeders N, Moreno-Reyes R et al. (2005) A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. *Transplantation* 79:108–15.

Worth H, Stammen D, Keck E (1994) Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. *American Journal of Respiratory and Critical Care Medicine* 150: 394–7.

Yamada H (1989) Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. [Japanese] *Nippon Naibunpi Gakkai Zasshi Folia Endocrinologica Japonica* 65: 603–14.

Yamaguchi K, Masuhara K, Yamasaki S et al. (2003) Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. *Bone* 33: 144–9.

Yildirim K, Gureser G, Karatay S et al. (2005) Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis. *Journal of Back and Musculoskeletal Rehabilitation* 18: 85–9.

Zein CO, Jorgensen RA, Clarke B et al. (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. *Hepatology* 42: 762–71.

Zhang RH, Chen KJ, Lu DX (2004) Clinical study on treatment of postmenopausal osteoporosis by Yigu capsule. *Chinese Journal of Integrated Traditional and Western Medicine* 24: 680–4.